Sandoz rolls out HCF biosimilar to AbbVie’s arthritis drug Humira
Swiss drugmaker Novartis through its generic and biosimilars unit Sandoz has introduced Hyrimoz (adalimumab-adaz), its high-concentration formulation (HCF) biosimilar to AbbVie arthritis treatment Humira. Hyrimoz HCF is approved